You are here

SteadyMed

United axes PAH program Trevyent, once bought for cheap in acquisition of a rival, after FDA feedback

United axes PAH program Trevyent, once bought for cheap in acquisition of a rival, after FDA feedback

Endpoints

United Therapeutics

Flag link:

4 Biotech and Pharma Stocks Projected to Rise 50% to 100%

4 Biotech and Pharma Stocks Projected to Rise 50% to 100%

24/7 Wall St

Intercept Pharmaceuticals

Intra-Cellular Therapies

Flag link:

Drug-device biotech SteadyMed swings for a $55M IPO

Drug-device biotech SteadyMed swings for a $55M IPO

Fierce Biotech

Flag link: